VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Garon on Differences Between Antiangiogenic Agents in Lung Cancer

Edward B. Garon, MD
Published: Friday, Sep 08, 2017



Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Unlike bevacizumab (Avastin), ramucirumab (Cyramza) and nintedanib (Ofev) target the VEGF receptor. Ramucirumab is a monoclonal antibody and nintedanib is a tyrosine kinase inhibitor.

There have been multiple attempts to add a TKI to chemotherapy in order to achieve the same benefits seen with bevacizumab plus chemotherapy, says Garon.
 


Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Unlike bevacizumab (Avastin), ramucirumab (Cyramza) and nintedanib (Ofev) target the VEGF receptor. Ramucirumab is a monoclonal antibody and nintedanib is a tyrosine kinase inhibitor.

There have been multiple attempts to add a TKI to chemotherapy in order to achieve the same benefits seen with bevacizumab plus chemotherapy, says Garon.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x